(Press-News.org) Charlottesville, VA (April 9, 2013). Neurosurgeons at the University of Texas–Houston and Children's Memorial Hermann Hospital (Houston, Texas) report on the success they achieved when they removed a hypothalamic hamartoma (HH) from a 10-year-old girl to combat hyperphagia (excessive appetite and compulsive overeating) and consequent unhealthy weight gain. To the best of the authors' knowledge, this is the first time resection of an HH was performed for this particular reason. Findings in this case are reported and discussed in "Successful treatment of hyperphagia by resection of a hypothalamic hamartoma. Case report," by Yoshua Esquenazi, M.D., David I. Sandberg, M.D., and Harold L. Rekate, M.D., published today online, ahead of print, in the Journal of Neurosurgery: Pediatrics.
The patient was a 10-year-old girl who for three years had been treated medically for precocious (premature) puberty due to the presence of a hypothalamic hamartoma (HH), a noncancerous lesion in the brain. Treatment involved monthly intramuscular injections of a gonadotropin-releasing hormone (GnRH) analog. This therapy slowed the girl's sexual maturation but did nothing to curb her compulsive eating and excessive weight gain, which is often associated with precocious puberty due to HH. By the time the patient was 10 years old, she weighed 103 kilograms (227 pounds) and she continued to gain 5 pounds per month on average. Counseling on nutrition was ineffective.
The girl's continual weight gain was of great concern. Medication and counseling had done nothing to retard her overeating. Although the neurosurgeons could find no precedent in the literature, they decided to remove the hypothalamic hamartoma (HH) in the hopes that this would control the patient's hyperphagia. Dr. Esquenazi and colleagues call it a "last-ditch effort." The surgery went smoothly, the authors report, and immediately thereafter the girl's appetite diminished and she began eating smaller portions. Eighteen months after surgery, the patient's weight was still the same as it had been before the operation, but it no longer increased, which was the goal of surgery.
"The decision to proceed with this surgery," according to Dr. Sandberg, "was undertaken with great thought and after numerous discussions with the patient's family. We were cautious about proceeding with a major operation in which the probability of success was completely unknown. The patient, her family, and treating physicians were all delighted with the outcome."
A hypothalamic hamartoma (HH) is a rare, congenital, disorganized collection of normal brain cells (glia and neurons) located in or around the hypothalamus. Although some HHs are asymptomatic, others are responsible for seizures, particularly gelastic ones (which present as inappropriate outbursts of laughing or crying), behavioral or cognitive problems, or precocious puberty (33% of cases of precocious puberty are caused by HHs). Precocious puberty is usually treated medically with a GnRH analog until the patient reaches 12 or 13 years of age. Removal of the HH by surgery is recommended when medical therapy fails to correct the hormone imbalance. In the present case, medical therapy was effective in arresting sexual maturation, but surgery was required to cure the patient's hyperphagia.
###
Esquenazi Y, Sandberg DI, Rekate HL. Successful treatment of hyperphagia by resection of a hypothalamic hamartoma. Case Report. Journal of Neurosurgery: Pediatrics, published online, ahead of print, April 9, 2013; DOI: 10.3171/2013.2.PEDS12552.
Disclosure: The authors report no conflict of interest concerning the materials or methods used in the study or the findings specified in this paper.
For additional information, please contact:
Ms. Jo Ann M. Eliason, MA, ELS
Communications Manager
Journal of Neurosurgery Publishing Group
One Morton Drive, Suite 200
Charlottesville, VA 22903
Fax 434-924-2702
The Journal of Neurosurgery: Pediatrics is a monthly peer-reviewed journal focused on diseases and disorders of the central nervous system and spine in children. This journal contains a variety of articles, including descriptions of preclinical and clinical research as well as case reports and technical notes. The Journal of Neurosurgery: Pediatrics is one of four monthly journals published by the JNS Publishing Group, the scholarly journal division of the American Association of Neurological Surgeons. Other peer-reviewed journals published by the JNS Publishing Group each month include the Journal of Neurosurgery, Neurosurgical Focus, and the Journal of Neurosurgery: Spine. All four journals can be accessed at http://www.thejns.org.
Founded in 1931 as the Harvey Cushing Society, the American Association of Neurological Surgeons (AANS) is a scientific and educational association with more than 8,300 members worldwide. The AANS is dedicated to advancing the specialty of neurological surgery in order to provide the highest quality of neurosurgical care to the public. All active members of the AANS are certified by the American Board of Neurological Surgery, the Royal College of Physicians and Surgeons (Neurosurgery) of Canada or the Mexican Council of Neurological Surgery, AC. Neurological surgery is the medical specialty concerned with the prevention, diagnosis, treatment and rehabilitation of disorders that affect the entire nervous system including the brain, spinal column, spinal cord, and peripheral nerves. For more information, visit http://www.AANS.org. END
Removal of hypothalamic hamartoma curbs compulsive eating and excessive weight gain
2013-04-09
ELSE PRESS RELEASES FROM THIS DATE:
Mayo researchers identify gene variations that predict chemotherapy side effects
2013-04-09
ROCHESTER, Minn. -- Seemingly benign differences in genetic code from one person to the next could influence who develops side effects to chemotherapy, a Mayo Clinic study has found. The study identified gene variations that can predispose people to chemotherapy-induced peripheral neuropathy, a condition that is hard to predict and often debilitating enough to cause cancer patients to stop their treatment early. Results of the research were presented today at the American Association for Cancer Research Annual Meeting 2013 in Washington, D.C.
The study, which implicates ...
Ranibizumab may prevent retinal detachment side effect
2013-04-09
BOSTON (April 9, 2013) – Proliferative vitreoretinopathy (PVR), or the formation of scar tissue in the eye, is a serious, sight-threatening complication in people recovering from surgical repair of retinal detachment. PVR is difficult to predict, lacks effective treatment options, and substantially reduces an individual's quality of life. Each year 55,000 people are at risk for developing PVR in the United States alone.
A new study carried out by scientists from The Schepens Eye Research Institute/Massachusetts Eye and Ear and the Department of Ophthalmology, Harvard ...
AACR news: Misregulated genes common to tobacco-related cancers offer potential new prognostic tool
2013-04-09
Believe it or not, while researchers have explored which genes are mutated in each type of tobacco-associated cancer, until now no one had thought to look across these types for common genes that might predict patient outcomes. Results presented at the AACR Annual Meeting 2013 show that in lung and bladder cancers, genes related to the regulation of the cell cycle are associated with poor patient outcomes.
"We ultimately envision this as a prognostic tool to predict survival rates for people with tobacco related cancers. Recognizing patients with high expression of these ...
AACR news: K9 osteosarcoma samples identify drivers of metastasis in pediatric bone cancer
2013-04-09
Human osteosarcoma samples are hard to come by, making the disease difficult to study. However, K9 bone cancer is genetically indistinguishable from the human form of the disease, and over 10,000 canine patients develop the disease every year. Research from the University of Colorado Cancer Center and the Colorado State University Flint Animal Cancer Center presented at the AACR Annual Meeting 2013 used easily available K9 osteosarcoma samples to discover a novel protein that governs metastasis and chemoresistance in pediatric osteosarcoma.
"We have a pediatric osteosarcoma ...
AACR news: New target plus new drug equals death of melanoma cells
2013-04-09
Collaborative research presented by the University of Colorado Cancer Center, the University of North Carolina at Chapel Hill, Harvard Medical School and the University of Pittsburgh, at the American Association for Cancer Research (AACR) Annual Conference, shows that the protein receptor Mer is overexpressed in melanoma and that the investigational drug UNC1062 blocks Mer survival signaling in these cells, killing them.
"It's exciting in that Mer receptor expression correlates so perfectly with disease progression. It's tiered – you see a bump in expression as you transition ...
AACR news: Rigosertib Phase 1 results lead to disease-focused Phase 2 development
2013-04-09
Results of a phase 1 clinical trial reported at the American Association for Cancer Research (AACR) annual conference show that orally administered Rigosertib is well tolerated in patients with advanced solid tumors. This is the first trial in which orally administered Rigosertib, a dual kinase inhibitor, was studied in solid tumors. Intravenously rigosertib is already in phase 3 clinical trials for myelodysplastic syndrome and pancreatic cancer and oral rigosertib is being studied in a pair of Phase II trials in lower-risk transfusion dependent MDS patients. The drug ...
AACR news: Little molecule makes big difference in bladder cancer metastasis
2013-04-09
In order to kill, bladder cancer must metastasize, most commonly to the lung – what are the differences between bladder cancers that do and do not make this deadly transition? Research presented by the Director of the University of Colorado Cancer Center at the AACR Annual Meeting 2013 shows that one big difference is a little molecule known as hsa-miR-146a.
Messenger RNA or mRNA carries gene blueprints to sites where the plans are read and made into proteins, and to a large degree microRNA or miRNA tells mRNA what to do. Theodorescu's work shows that in 256 samples of ...
AACR news: Six2 homeoprotein allows breast cancer cells to detach and metastasize
2013-04-09
In results presented at the AACR Annual Meeting 2013, researchers from the University of Colorado Cancer Center show that the Six2 homeoprotein, while not involved in primary tumor growth, allows cells to detach from substrate and survive their transition through the bloodstream to faraway sites of metastasis.
"Here we show for the first time that Six2 causes breast cancer progression. It's this metastasis, especially to the lung, that can eventually be deadly and so perhaps even more so than affecting the size of the primary tumor, we are especially excited to present ...
1-2 punch could be key in treating blindness
2013-04-09
EAST LANSING, Mich. — Researchers have discovered that using two kinds of therapy in tandem may be a knockout combo against inherited disorders that cause blindness. While their study focused on man's best friend, the treatment could help restore vision in people, too.
Published in the journal Molecular Therapy, the study builds on earlier work by Michigan State University veterinary ophthalmologist András Komáromy and colleagues. In 2010, they restored day vision in dogs suffering from achromatopsia, an inherited form of total color blindness, by replacing the mutant ...
High pressure gold nanocrystal structure revealed
2013-04-09
A major breakthrough in measuring the structure of nanomaterials under extremely high pressure has been made by researchers at the London Centre for Nanotechnology (LCN).
Described in Nature Communications, the study used new advances in x-ray diffraction to image the changes in morphology of gold nanocrystals under pressures of up to 6.5 gigapascals.
Under high pressures, imaging methods such as electron or atomic force microscopy are not viable, making x-ray diffraction imaging the only option. However, until recently, focusing an image created with this method ...